Mat D Davis
Mat D Davis
Teva Pharmaceuticals
Verified email at
Cited by
Cited by
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study
PM Doraiswamy, RA Sperling, RE Coleman, KA Johnson, EM Reiman, ...
Neurology 79 (16), 1636-1644, 2012
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study
HH Fernandez, SA Factor, RA Hauser, J Jimenez-Shahed, WG Ondo, ...
Neurology 88 (21), 2003-2010, 2017
Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals
RA Sperling, KA Johnson, PM Doraiswamy, EM Reiman, AS Fleisher, ...
Neurobiology of aging 34 (3), 822-831, 2013
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial
KE Anderson, D Stamler, MD Davis, SA Factor, RA Hauser, J Isojärvi, ...
The Lancet Psychiatry 4 (8), 595-604, 2017
Rasagiline for mild cognitive impairment in Parkinson's disease: a placebo‐controlled trial
D Weintraub, RA Hauser, JJ Elm, F Pagan, MD Davis, A Choudhry, ...
Movement Disorders 31 (5), 709-714, 2016
Discordance between non-HDL-cholesterol and LDL-particle measurements: Results from the Multi-Ethnic Study of Atherosclerosis
EM DeGoma, MD Davis, RL Dunbar, ER Mohler, P Greenland, B French
Atherosclerosis 229 (2), 517-523, 2013
The practice of cognitive-behavioural hypnotherapy: A manual for evidence-based clinical hypnosis
DJ Robertson
Routledge, 2018
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
NG LaRocca, LD Hudson, R Rudick, D Amtmann, L Balcer, R Benedict, ...
Multiple Sclerosis Journal 24 (11), 1469-1484, 2018
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate …
O Khan, P Rieckmann, A Boyko, K Selmaj, N Ashtamker, MD Davis, ...
Multiple Sclerosis Journal 23 (6), 818-829, 2017
A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
CJ Ross, F Towfic, J Shankar, D Laifenfeld, M Thoma, M Davis, B Weiner, ...
Genome medicine 9 (1), 1-15, 2017
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia
HH Fernandez, D Stamler, MD Davis, SA Factor, RA Hauser, ...
Journal of Neurology, Neurosurgery & Psychiatry 90 (12), 1317-1323, 2019
O Connell T, Johnson S, Cline S, Merikle E, Martenyi F, et al. Estimating Alzheimer’s disease progression rates from normal cognition through mild cognitive impairment and …
M Davis
Curr Alzheimer Res 15, 777-88, 2018
Comparative utility of disability progression measures in PPMS: analysis of the PROMiSe data set
MW Koch, GR Cutter, G Giovannoni, BMJ Uitdehaag, JS Wolinsky, ...
Neurology-Neuroimmunology Neuroinflammation 4 (4), 2017
Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study
MD Davis, N Ashtamker, JR Steinerman, V Knappertz
Neurology-Neuroimmunology Neuroinflammation 4 (2), 2017
149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study
KE Anderson, MD Davis, SA Factor, RA Hauser, LF Jarskog, ...
CNS Spectrums 23 (1), 92-93, 2018
Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study (S4. 009)
R Hauser, H Barkay, H Fernandez, S Factor, J Jimenez-Shahed, N Gross, ...
Neurology 92 (15 Supplement), 2019
Academic Seismic Portal (ASP) at UTIG
G Christeson, T Shipley, L Gahagan, K Johnson, M Davis
University of Texas Institute for Geophysics, Austin, TX, http://www-udc. ig …, 2017
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing‐Remitting Multiple Sclerosis
R Zivadinov, MG Dwyer, DP Ramasamy, MD Davis, JR Steinerman, ...
Journal of Neuroimaging 25 (6), 989-995, 2015
Seismic Data Center, University of Texas Institute for Geophysics
T Shipley, L Gahagan, K Johnson, M Davis
URL http://www. ig. utexas. edu/sdc/(Last accessed October 23, 2013), 2005
Addressing involuntary movements in tardive dyskinesia (AIM-TD): effect of fixed-dose deutetrabenazine by baseline comorbidities (S56. 006)
KE Anderson, SA Factor, MD Davis, RA Hauser, J Isojarvi, ...
Neurology 88 (16 Supplement), 2017
The system can't perform the operation now. Try again later.
Articles 1–20